Efficacy of Tocilizumab in Primary Sjögren's Syndrome.

Inclusion Criteria : * Patient with primary Sjögren's syndrome according to the European - American consensus group criteria. * ESSDAI score ≥ 5. * In women in childbearing age, effective contraception during treatment and 3 months following treatment discontinuation. Exclusion Criteria: * Patient with previous history of therapy with tocilizumab. * Prednisone treatment introduced two weeks before inclusion or a change in this drug dose within two weeks before inclusion. * A prednisone dose ≥ 15 mg per day. * Non-steroidal anti-inflammatory drugs, pilocarpine hydrochloride, cyclosporine, cimeviline if introduced within two weeks before inclusion. * Therapy with methotrexate, Hydroxychloroquine, chloroquine, quinacrine, leflunomide, psychoactive drug if introduced within 8 weeks before inclusion or a dose change within 8 weeks before inclusion. * Treatment with azathioprine or mycophenolate mofetil within 8 weeks before inclusion. * Live and live attenuated vaccines given within 4 weeks before inclusion. * Any biologic treatment within 6 month before inclusion. * Treatment with cyclophosphamide, intravenous immunoglobulin therapy or plasmapharese therapy in the last 6 months before inclusion. * Systemic auto-immune disease. * Patient with previous history of diverticular perforations, complications of diverticulitis, peritonite or inflammatory bowel disease (such as Crohn's disease and Colitis ulcerative). * Patient with history of severe infection within 4 weeks before inc…